Navigation Links
Boehringer Ingelheim Unveils Diabetes Pipeline
Date:6/6/2009

eline to week 12.(1) Out of the 333 randomized patients, 268 patients received double-blind treatment with linagliptin (1 mg, n=65; 5 mg, n=66; 10 mg, n=66) or placebo.(1) An open-label arm with 65 patients on glimepiride was added for descriptive control.(1)

Additional results from the study

The addition of linagliptin to metformin treatment for 12 weeks resulted in clinically relevant and statistically significant reductions in HbA1c and fasting blood sugar or fasting plasma glucose (FPG) levels (p-values of less than 0.05%):(1)

  • Statistically significant reductions in mean HbA1c levels with linagliptin 5 mg and 10 mg compared with metformin alone (both p<0.001) were observed from week four though week 12.(1)
  • In addition, all linagliptin doses showed significant reductions in FPG levels compared with metformin alone (placebo-corrected mean changes from baseline; -19.2 mg/dL for 1 mg, -34.7 mg/dL for 5 mg, and -29.0 mg/dL for 10 mg).(1)
  • In the open-label comparator arm, the placebo-corrected mean change from baseline in HbA1c was -0.90 percent.(1)
  • More than 85% of the patients receiving the 5mg and 10mg doses of linagliptin demonstrated greater that or equal to 80% DPP-4 inhibition at trough at week 12(1)
  • HbA1c reductions of at least 0.5 percent were achieved in 44 percent to 53 percent of patients on linagliptin, but only in 13 percent of the patients receiving metformin alone.(1)

About type 2 diabetes

There are approximately 23.6(5) million Americans and 246 million people worldwide(6) with diabetes. Type 2 diabetes is the most common type of diabetes accounting for more than 90% of all diabetes cases in the developed world.(7) Every ten seconds two people develop diabetes and one person dies from diabetes-related causes around the world.(6) Each
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
2. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
3. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
4. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
5. OmegaGenesis Unveils Novel Nanotechnology Platform With Broad Biomedical Applications
6. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
7. NeoVista Unveils 18-month Data on Novel Wet AMD Therapy at Retina Society Meeting
8. Oregon Tourism Commission Unveils New Online Customer Service Training Program
9. AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
10. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
11. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... -- Neurobiological Technologies, Inc. (formerly NTII) ("NTI") ... Dissolution with the Secretary of State of the ... Certificates of Dissolution generally become effective upon filing. ... of NTI under the Delaware General Corporation Law. ... Certificate of Dissolution, NTI also closed its stock ...
(Date:12/17/2009)... 17 Medela announced today the award ... Collection Campaign in honor of the March of ... participated in the campaign, voting for their preferred ... hospitals will receive $5,000 in neonatal human milk ... at Gulfport, Gulfport, MS. ,, * St. John ...
(Date:12/17/2009)... 17 Decision Resources, one of the ... and healthcare issues, finds that the cost of ... and side-effect profile, are cited most frequently by ... of Avastin for non-small-cell lung cancer treatment in ... ,, The new Special European Physician & Payer ...
Breaking Medicine Technology:Medela Announces Virtual Human Milk Collection Campaign Award Recipients in Honor of 2009 Prematurity Awareness Month 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 2Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer 3New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 53411 1New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 53411 2New Book by Leading Authority Responds to National Initiative to Bring Undergraduate Public Health Education to All American Colleges and Universities 53411 3 Study finds increased sibling risk of obstructive sleep apnea in children 53408 1 Study finds increased sibling risk of obstructive sleep apnea in children 53408 2Race ethnicity family income and education associated with sugar consumption 9451 1Race ethnicity family income and education associated with sugar consumption 9451 2
... SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- ... on the,treatment of central nervous system disorders ... that the Company will present data,about its ... on markers of cardiovascular disease (visceral fat, ...
... U.S.-based subsidiary of,Pharmexa A/S, presents selected data ... Influenza Conference entitled, "Options for,the Control of ... The,data show that a "universal" vaccine designed ... mice against,lethal experimental influenza virus challenge. , ...
Other Medicine Technology:Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 2Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 3Pharmexa A/S (DK) - Pharmexa presents data from influenza program 2
(Date:12/17/2009)... ANGELES, Dec. 17 Pacific ... Energy-X lip balms, today announced the launch of ... therapeutic heating/cooling treatment packs are specifically designed to ... developed in a variety of applications. Researchers behind ... a specialized corn to hold temperatures for long ...
(Date:12/17/2009)... -- ,Hopenhagen, the city is calling itself, that ... conference on climate change. Narconon has its European ... the worldwide Narconon drug education and ... climate change. But the streets thrum with student ... with flashing blue lights - a youth protest ...
(Date:12/17/2009)... stage at the Fisher Theatre on Dec. 17 for the Detroit-area,premiere ... survivors will be the real stars of the show. , ... ... takes the stage at the Fisher Theatre on Dec. 17 for ... cancer patients and cancer survivors will be the real stars ...
(Date:12/17/2009)... now able to access trusted medical information using virtually any ... ... (PRWEB) December 17, 2009 -- Skyscape, Inc., the world’s most ... the Internet, has launched a mobile clinical decision application on ... now available on most smart phone devices, making the ability ...
(Date:12/17/2009)... LOS ANGELES, Dec. 17 On the heels ... course for the 2010 race, LA Marathon officials ... 60 non-profit organizations raising funds for causes ranging from ... waters. ,, The expanded charity program is in line ... believes the Marathon has the potential to be a ...
Breaking Medicine News(10 mins):Health News:Thermal-Aid Bears Provide Warm Comfort to Children at Penny Lane for the Holidays 2Health News:Save the Planet. Stop Smoking Dope, Says Narconon 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 2Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 3Health News:Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android 4Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 2Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 3Health News:LA Marathon Unveils Expanded Charity Program; Sixty Official Charities to Take Part in 2010 Race 4
... Case Medical Center has been recognized for its ... Association,s Get With The GuidelinesSM for coronary artery ... Case Medical Center (UHCMC) has received the Get ... coronary artery disease, Silver Performance Achievement Award in ...
... causes the baggy lower eyelids that come with aging, but ... eye socket is the primary culprit. , As a result, ... for patients seeking to address this common complaint. , The ... Journal of Plastic and Reconstructive Surgery , is the first ...
... of SUNY Downstate Medical Center leads research for local patients , ... ... without the ability to concentrate and focus on the things you enjoy ... would be like, struggling to remember what you just talked about or ...
... is a break-through Nitinol wire product which features an ... Hf acid solutions which cause embrittlement. The resulting ... through other known methods. , ... ...
... in Generic Market Information Offers Single Authoritative, Source of ... ... API Manufacturers, JAKARTA, Indonesia, Aug. 26 /Xinhua-PRNewswire/ -- Indonesia,s ... from launch of two solutions in the market by the,Scientific ...
... AMICAS, Inc. (Nasdaq: AMCS ),a leader in radiology and medical ... scheduled to,address investors at the Thomas Weisel Partners Healthcare Conference 2008,being ... ), WHEN: ... -- Presentation begins promptly at 10:20 ...
Other Medicine News:Health News:University Hospitals Case Medical Center recognized by American Heart Association 2Health News:University Hospitals Case Medical Center recognized by American Heart Association 3Health News:Why do eyelids sag with age? UCLA study answers mystery 2Health News:New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia 2Health News:NitiBrite&#8482; - Break-through in Nitinol Wire Product for Medical Devices 2Health News:Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters 2Health News:Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters 3Health News:AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2008 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: